GILD

Gilead SciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$170.00

+33.3% vs current

Most likely

Base case

60%

Probability

Target price

$146.84

+15.1% vs current

B-

Bear case

20%

Probability

Target price

$103.00

-19.3% vs current

AI sentiment snapshot

Latest data as of 2026-02-11

AI commentary

Market tone is mixed: consensus median sits near our base case while select broker upgrades have pushed upside expectations toward the high‑$160s–$170s, signaling selective conviction on HIV strength [#SERP-4][#SERP-6]. The wide low–high spread reflects event-driven risk; near-term earnings and readouts will likely determine short-term direction.

RankAlpha Sentiment AI - 2026-02-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-12eventNext quarterly results (estimated)Medium impact

Estimated quarterly results event; date conservatively assumed as 2026-05-12 (no confirmed date disclosed here). Results can re-price shares if HIV/oncology revenues diverge from expectations [#SERP-4].

2027-02-11catalystHIV franchise sustained growth (Biktarvy/Cabenuva)High impact

Continued HIV product momentum could drive significant top-line upside over the next 12 months; recent analyst notes cite strong HIV sales as a reason for higher targets [#SERP-6].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-02-11 • Updated nightlySource: Internal modelMethodology